Global Coronary Atherectomy Devices Market

Bifurcation lesions refer to a coronary artery constriction that occurs next to or involves the origin of a vital side branch one does not want to lose. It occurs when plaque deposits accumulate, and the artery becomes too small for adequate blood flow to your heart. The main types of bifurcation lesions are one-stent and two-stent. One-stent bifurcation lesions refer to a procedure where the side branch is provisionally stented if the intervention is required owing to clinical complaints, angiographic results, or other adjunctive variables. The main branch is stented first in this approach. The bifurcation angle is determined by the internal angle between the main and side branches. These types of bifurcation lesions are applied in coronary and peripheral vascular. The bifurcation lesions market research report is one of a series of new reports from The Business Research Company that provides bifurcation lesions market statistics, including bifurcation lesions industry global market size, regional shares, competitors with a bifurcation lesions market share, detailed bifurcation lesions market segments, market trends and opportunities, and any further data you may need to thrive in the bifurcation lesions industry. This bifurcation lesions market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global bifurcation lesions market size grew from $2.25 billion in 2022 to $2.4 billion in 2023 at a compound annual growth rate (CAGR) of 6.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The bifurcation lesions market size is expected to grow to $3.18 billion in 2027 at a CAGR of 7.2%. The increase in geriatric population is expected to drive the growth of the bifurcation lesions market. People whose age is more than 60 years are more likely to suffer a heart attack, a stroke, or develop coronary heart disease and heart failure than younger people. In such cases, bifurcation lesions help treat the blood clots to allow adequate blood flow to your heart. For instance, according to the United Nations Department of Economic and Social Affairs' September 2020 report, the population aged 65 and above is projected to rise from 9.3% in 2020 to around 16.0% in 2050. Furthermore, according to October 2021 published factsheet by World Health Organization, there will be 1.4 billion individuals over the age of 60 in the world by 2030, up from 1 billion in 2020. Therefore, the increasing geriatric population will drive the bifurcation lesions market. The advancement in devices used in imaging and procedures is a key trend that is gaining popularity in the bifurcation lesions market. Major companies operating in the market are concentrating their efforts on advancements in existing devices used in imaging and procedures. For instance, Advanced Bifurcation Systems (ABS), a clinical-stage medical device firm with a unique bifurcation stenting solution to standardize the treatment of all bifurcation lesions in coronary angioplasties, has a platform featuring the only modular self-aligning stent technology to evenly structure bifurcations. The ABS platform is a unique single system that reduces the need for repeat procedures and enables effective bifurcation stenting treatment. In September 2021, Boston Scientific Corporation, a US-based biomedical/biotechnology engineering firm and manufacturer of medical devices used in interventional medical specialties, acquired Devoro Medical, Inc. for an undisclosed amount. Through this acquisition, Boston Scientific will focus on clot management and commercialization using the WOLF Thrombectomy Platform developed by Devoro Medical. Innovative non-console and lytic-free WOLF technology use finger-like prongs to extract and remove thrombi in the arterial and venous systems to target and quickly trap blood clots. This technology will enhance and broaden its selection of interventional strategies for thromboemboli, including the AngioJet Thrombectomy System and the EkoSonic Endovascular System (EKOS). Devoro Medical, Inc is a US-based developer of a medical device intended to restore blood flow. Major players in the bifurcation lesions market are Boston Scientific Corporation, Terumo Medical Corporation, Spectranetics, Medtronic, Cardinal Health, Abbott, Tryton Medical Inc., Advanced Bifurcation Systems, and Cook Medical. North America was the largest region in the bifurcation lesions market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bifurcation lesions market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the bifurcation lesions market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The bifurcation lesions market includes revenues earned by proximal main branch (MB), distal MB and side branch (SB). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.  The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global bifurcation lesions market is segmented - 1) By Types: One-Stent, Two-Stent 2) By Application: Coronary Vascular, Peripheral Vascular

The vascular grafts are used to repair the diseased or blocked blood vessel during the surgical procedure called vascular grafting or vascular bypass. Vascular grafting is performed to bypass a partial or complete blockage in an artery by reconnecting the blood vessels. This process improves the blood flow by redirecting blood from one area of the body to another. The main products of the vascular graft are hemodialysis access graft, endovascular stent graft, peripheral vascular graft, and coronary artery bypass graft. Endovascular stent graft refers to the method of minimally invasive method that is used to treat an aortic aneurysm and is performed to know the presence of abdominal pain, symptoms for the disease, and also for the size of the aneurysm. The various raw materials are polyester grafts, ePTFE, polyurethane grafts, and biosynthetic grafts. The various applications of vascular graft are coronary artery disease, aneurysm, vascular occlusion, and renal failure that are used by end-users such as hospitals and ambulatory surgical centres. The vascular graft market research report is one of a series of new reports from The Business Research Company that provides vascular graft market statistics, including vascular graft industry global market size, regional shares, competitors with a vascular graft market share, detailed vascular graft market segments, market trends and opportunities, and any further data you may need to thrive in the vascular graft industry. This vascular graft market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global vascular grafts market grew from $2.96 billion in 2022 to $3.21 billion in 2023 at a compound annual growth rate (CAGR) of 8.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The vascular grafts market is expected to grow from $4.37 billion in 2027 at a CAGR of 8.1%. The rising prevalence of vascular diseases is driving the growth of the global vascular grafts market. According to a study by the National Center for Biotechnology Information in the US, cardiovascular diseases are the leading cause of death in the world and according to the American Heart Association (AHA), the overall prevalence of myocardial infarction in the US was around 7.9 million per year, while the estimated annual incidence of a heart attack in the US is 720,000 new attacks and 335,000 recurrent attacks. According to a study by NHS Inform, a national health service of Scotland, every year around 20,000 coronary bypass grafts are carried out in England. Therefore, the high prevalence of vascular diseases is anticipated to drive the global vascular grafts market. The high cost of medical treatment and complications related to prosthetic grafts are expected to restrain global vascular grafts market growth. The cost of the CABG (coronary artery bypass graft) surgery is very high in western countries. For instance, in the US, the average cost of coronary artery bypass surgery is $40,000, which varies widely by region and facility. Moreover, several complications are associated with prosthetic grafts such as disruption of an infected anastomotic suture line due to rupture or pseudoaneurysm formation, sepsis, amputation, thromboembolism, chances of reinfection due to vascular grafts reconstruct, enteric fistulae, the spread of bacterial infection to other sites, and death. Thus, high treatment costs and complications related to prosthetic grafts are expected to restrain the market growth. Companies in the vascular graft market are increasingly investing in technological advances for the development of innovative vascular grafts, including customization of vascular grafts. For instance, RelayPro, a thoracic stent graft system recently launched by Terumo Aortic, is a low-profile device designed for patients with smaller access vessels in the treatment of thoracic endovascular aortic repair (TEVAR). It offers a broad range of diameters, lengths, tapers, and proximal configurations to the physicians. Both bare stent and non-bare stent (NBS) versions are available for this device and they can be customized to meet the patient’s specific anatomical needs. In June 2020, LeMaitre Vascular, a US-based medical device company, acquired Artegraft for $90 million. The acquisition the company expected to extend its product line with Artegraft’s innovative products and better serve the customers’ needs. Artegraft is a New Jersey-based seller of vascular grafts. Major players in the vascular graft market are B. Braun, C. R. Bard, Cardinal Health, Cook Medical, Endologix, LeMaitre Vascular, Medtronic PLC., Getinge, Terumo Medical Corporation, and Gore Medical. North America was the largest region in the vascular graft market in 2022. Western Europe was the second largest region in the global vascular graft market report. The regions covered in the global vascular graft market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the vascular graft market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The vascular grafts market consists of sales of polytetrafluoroethylene (Teflon), polyethylene terephthalate (Dacron), or a different person's vein (allograft). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global vascular grafts market is segmented - 1) By Product: Hemodialysis Access Graft, Endovascular Stent Graft, Peripheral Vascular Graft, Coronary Artery By-pass Graft 2) By Raw Material: Polyester Grafts, ePTFE, Polyurethane Grafts, Biosynthetic Grafts 3) By Application: Coronary Artery Disease, Aneurysm, Vascular Occlusion, Renal Failure 4) By End-User: Hospitals, Ambulatory Surgical Centers

A VEGF inhibitor is an inhibitor that prevents planned cell death by acting as an anti-apoptotic factor for hematopoietic cells. VEGF increases vascular permeability, which may make it easier for tumours to spread via the bloodstream and receive more oxygen and nutrients. The main types of vascular endothelial growth factor (VEGF) inhibitors are Avastin, Tecentriq, Cometriq, Eylea, and others. Avastin is a medication that helps people with wet age-related macular degeneration (AMD). It can also be employed to treat diabetic eye problems and other retinal issues. It's administered into the eye to help delay the loss of eyesight caused by certain disorders. The different routes of administration include oral, and intravenous and are used in oncology, ophthalmology, and others. The vascular endothelial growth factor (VEGF) inhibitor market research report is one of a series of new reports from The Business Research Company that provides vascular endothelial growth factor (VEGF) inhibitor market statistics, including vascular endothelial growth factor (VEGF) inhibitor industry global market size, regional shares, competitors with a vascular endothelial growth factor (VEGF) inhibitor market share, detailed vascular endothelial growth factor (VEGF) inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the vascular endothelial growth factor (VEGF) inhibitor industry. This vascular endothelial growth factor (VEGF) inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global vascular endothelial growth factor (vegf) inhibitor market grew from $8.27 billion in 2022 to $8.96 billion in 2023 at a compound annual growth rate (CAGR) of 8.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The vascular endothelial growth factor (vegf) inhibitor market is expected to grow from $12.11 billion in 2027 at a CAGR of 7.8%. The growing prevalence of cancer and macular degeneration diseases is expected to drive the vascular endothelial growth factor (VEGF) inhibitor market. For instance, in August 2022, according to this systematic review and meta-analysis published by the National Library of Medicine, a US-based medical library, age-related macular degeneration will affect 8–7% of the global population, with the illness affecting 196 million individuals in 2020 and rising to 288 million by 2040. Anti-vascular endothelial growth factor (anti-VEGF) agents halt the progression of the disease and improve vision. A vascular endothelial growth factor (VEGF) inhibitor slows and restricts tumor growth during cancers. Hence, the rising prevalence of cancer along with macular degeneration disease aids in the growth of the vascular endothelial growth factor (VEGF) inhibitor market over the forecast period. Side effects caused by VEGF inhibitors are expected to hinder the vascular endothelial growth factor (VEGF) inhibitor market. Side effects of treatment with VEGF-targeting angiogenesis inhibitors include hemorrhage and clots in the arteries, which results in a stroke or heart attack, hypertension, reversible posterior leukoencephalopathy syndrome, and impaired wound healing, and protein in the urine. For instance, Bevacizumab, a biosimilar drug approved by FDA, has side effects such as impaired wound healing, hypertension, bleeding, and gastrointestinal perforations. Side effects caused by VEGF inhibitors hinder the growth of the vascular endothelial growth factor (VEGF) inhibitor market. Key players operating in the industry are undergoing various collaborations and partnerships to expand their product portfolio by developing new products. For instance, in May 2020, AbbVie, a US-based biopharmaceutical company acquired Allergan, Inc., a US-based pharmaceutical company focused on eye care. This acquisition establishes a biopharma firm with leadership roles in vital therapeutic areas such as hematologic oncology, immunology, Allergan Aesthetics, and neuroscience. Furthermore, in January 2020, Exonate, a biotechnology company, collaborated with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson for the development of a new eye drop for the treatment of retinal vascular diseases. Exonerate developed small molecules that inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) through the selective inhibition of serine/threonine-protein kinase (SRPK1)-mediated VEGF splicing. In May 2020, AbbVie Inc., a US-based biopharmaceutical company, acquired Allergan plc for an amount of $63 billion. This acquisition is expected to give AbbVie Inc. an enhanced long-term growth potential along with a growing dividend and investment in innovation in each of Allergan plc’s therapeutic categories. Allergan plc is an Ireland-based pharmaceutical company engaged in the manufacturing of drugs and medical devices in the field of eye care, medical aesthetics, gastroenterology, and the central nervous system. Major players in the vascular endothelial growth factor (VEGF) inhibitor market are Pfizer, Amgen, Roche, Xbrane Biopharma AB, Genentech Inc., AstraZeneca PLC., Bayer AG, Eli Lilly and Company and Allergan PLC. North America was the largest region in the vascular endothelial growth factor (VEGF) inhibitor market in 2022. Middle East is expected to be the fastest-growing region in the global vascular endothelial growth factor (VEGF) inhibitor market during the forecast period. The regions covered in the global vascular endothelial growth factor (VEGF) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the vascular endothelial growth factor (VEGF) inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The vascular endothelial growth factor (VEGF) inhibitor market consists of sales of nexavar, sunitinib, nilotinib, pazopanib, and dasatinib. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global vascular endothelial growth factor (VEGF) inhibitor market is segmented - 1) By Drugs Type: Avastin, Tecentriq, Cometriq, Eylea, Other Drug Types 2) By Route Of Administration: Oral, Intravenous 3) By Application: Oncology, Ophthalmology, Other Applications

An intravascular catheter is a device typically comprised of a hollow fibre through which blood flows and an immunoisolating membrane separates the transplanted cells from the blood. The intravascular catheters are used for the administration of fluids, medication, blood products, and nutrition, which typically goes into a large vein in the arm or chest. The main intravascular catheter products include short PIVC and integrated/closed PIVC. Short peripheral intravenous catheters (PIVC) are less than or equal to 3 inches in length and are used for intravenous medication and are predominantly inserted in general wards. The different intravascular catheter applications include oncology, gastroenterology, renal disease, infectious diseases and other applications which are used by end-users including hospitals, clinics, ambulatory surgical center and homecare. The intravascular catheters market research report is one of a series of new reports from The Business Research Company that provides intravascular catheters market statistics, including intravascular catheters industry global market size, regional shares, competitors with an intravascular catheters market share, detailed intravascular catheters market segments, market trends and opportunities, and any further data you may need to thrive in the intravascular catheters industry. This intravascular catheters market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global intravascular catheters market size grew from $5.9 billion in 2022 to $6.66 billion in 2023 at a compound annual growth rate (CAGR) of 12.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The intravascular catheters market size is expected to grow to $10.32 billion in 2027 at a CAGR of 11.6%. The rising hospitalization rate owing to the high prevalence of chronic diseases is driving the growth of the intravascular catheters market. Globally, the prevalence of chronic illnesses and ailments is rising. Intravascular catheters are used for taking samples for tests and fluids, nutrients, and blood intake during the treatment of chronic diseases. According to an estimation by a German healthcare company, Fresenius Medical Care, the number of people suffering from chronic kidney failure is expected to increase from 3.7 million patients in 2020 to 4.9 million by 2025. Therefore, the rising hospitalization rate owing to the high prevalence of chronic diseases is expected to propel the growth of the intravascular catheters market over the coming years. The product innovations are a key trend gaining popularity in the intravascular catheters market. Major players in the intravascular catheters market are focusing on innovation of new products with advanced features to strengthen their position. For instance, in July 2022, B. Braun Medical Inc., a German-based medical and pharmaceutical device manufacturing company, introduced Introcan Safety 2 IV Catheter with one-time blood control making IV access safer for the clinician by lowering the danger of blood exposure and needle stick accidents. Furthermore, in March 2022, Shockwave Medical Inc., a firm that creates and sells medical devices, introduced the Shockwave M5+ catheter is particularly made to treat calcified lesions in the iliac, femoral, iliofemoral, popliteal, infra-popliteal, and renal arteries in the lower limbs that are otherwise difficult to treat. In January 2021, Prunus Technology Co., Ltd., a Shenzhen-based developer and manufacturer of various medical equipment, acquired Biosensors International Group, Ltd for an undisclosed amount. Through this acquisition, Prunus Technology expanded into central venous catheters, pressure transducers, pulmonary artery catheters, pacing catheters, thrombolysis catheters, urinary catheters and other medical consumables. Biosensors International Group, Ltd. is a Singapore-based company specializing in the critical care consumables business. Major players in the intravascular catheters market are Cook Medical, Smiths Medical, Edwards Life Sciences Corporation, Medtronic Inc., Johnson & Johnson, McKesson Medical Surgical Inc., Terumo Corporation, Abbott Laboratories Inc., Boston Scientific Corp., Getinge AB, Coloplast Corp., Cardinal Health, Conavi Medical, Infraredx Inc., BD, MAQUET Holding BV & Co KG, Vitality Medical, BBraun, Koninklijke Philips NV, Lumend Corporation, COVIDien Ag, Acist Medical Systems, Biotronic SE, & COKG, Biosense Webster Inc., Cordis, QX Medical and Teleflex Corporated. North America was the largest region in the intravascular catheters market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravascular catheters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the intravascular catheters market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The intravascular catheters market consists of sales of pulmonary artery catheters and pacing wires. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global intravascular catheters market is segmented - 1) By Product: Short PIVC, Integrated/Closed PIVC 2) By Application: Oncology, Gastroenterology, Renal Disease, Infectious Diseases, Other Applications 3) By End-Use: Hospitals, Clinics, Ambulatory Surgical Center, Homecare

Peripheral IV catheters refer to a thin, flexible tube that is placed into a vein to deliver medications and nutritional supplements. Peripheral intravenous catheters (PIVCs) are used for therapeutic purposes such as the administration of medications, fluids, or blood products, as well as blood sampling. The main types of peripheral IV catheters are short peripheral intravenous catheters and integrated/closed peripheral intravenous catheters (PIVC). A short peripheral catheter is less than 3 inches long. The technology used in peripheral IV catheters is conventional peripheral intravenous catheters, a safety PIVC that is used across various end-users such as hospitals, clinics, ambulatory surgical centers, and home healthcare. The peripheral IV catheters market research report is one of a series of new reports from The Business Research Company that provides peripheral IV catheters market statistics, including peripheral IV catheters industry global market size, regional shares, competitors with a peripheral IV catheters market share, detailed peripheral iv catheters market segments, market trends and opportunities, and any further data you may need to thrive in the peripheral IV catheters industry. This peripheral IV catheters market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global peripheral iv catheters market size grew from $4.8 billion in 2022 to $4.83 billion in 2023 at a compound annual growth rate (CAGR) of 0.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The peripheral iv catheters market size is expected to grow to $6.5 billion in 2027 at a CAGR of 7.7%. The rising prevalence of chronic diseases is expected to propel the growth of the peripheral IV catheters market. Peripheral intravenous catheters are commonly used in the management of various chronic diseases such as cancer, cardiovascular diseases, and others. According to the World Health Organization (WHO), a specialized agency of the United Nations, in 2020, cancer is a leading cause of death worldwide, accounting for approximately 10 million deaths, or nearly one in six deaths globally. Cancer-causing infections like human papillomavirus (HPV) and hepatitis are mostly responsible for nearly 30% of cancer cases in low and lower-middle-income countries. Therefore, the rising prevalence of chronic diseases is expected to propel the growth of the peripheral IV catheters market. Technological advancements are shaping the peripheral IV catheters market. Many companies in the market are developing new products to provide technically enhanced products to their users. B. Braun Medical, a US-based infusion therapy company, launched the new Introcan Safety 2 IV cathetar with one-time blood control. The new product makes the IV access safer for clinicians by reducing the risk of needlestick injuries. In July 2021, BD (Becton, Dickinson, and Company), a global medical technology company, acquired Velano Vascular for an undisclosed amount. Through the acquisition, BD can now help health care providers eliminate multiple needlesticks for blood sample collection, reducing pain and discomfort while delivering quality outcomes and increased patient satisfaction, thanks to Velano Vascular and its innovative, needle-free technology that enables high-quality blood draws from existing peripheral intravenous catheter (PIVC) lines. Velano Vascular is a California-based medical equipment manufacturer; whose needle-free technology enables high-quality blood draws from existing PIVC lines. Major players in the peripheral IV catheters market are Becton, Dickinson and Company, B. Braun Melsungen AG, Smiths Medical Inc., Vygon, Terumo Corporation, Teleflex Incorporated, NIPRO Medical Corporation, Argon Medical Devices, Inc., Medical Components, Inc., Vascular Pathways, Inc., Tangent Medical Technologies, Inc., Vigmed AB, Venner Medical, and C. R. Bard, Inc. North America was the largest region in the peripheral IV catheters market in 2022. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the peripheral IV catheters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the peripheral iv catheters market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The peripheral IV catheters market consists of sales of long peripheral intravenous catheters (long PIVC), and midline catheters. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global peripheral iv catheters market is segmented - 1) By Product Type: Short Peripheral Intravenous Catheters, Integrated/Closed Peripheral Intravenous Catheters (PIVC) 2) By Technology: Conventional Peripheral Intravenous Catheters (PIVC), Safety Peripheral Intravenous Catheters (PIVC) 3) By End User: Hospitals, Clinics, Ambulatory Surgical Centers, Home Healthcare

Cardiovascular devices are used to monitor and control the irregular heartbeats and heart rhythm disorders. The main types in the cardiovascular devices market are cardiovascular surgery devices and equipment, cardiac rhythm management (CRM) devices and equipment, interventional cardiology devices and equipment, defibrillator devices and equipment, peripheral vascular devices and equipment, prosthetic heart valve devices and equipment, electrophysiology devices and equipment, and cardiac assist devices and equipment. Defibrillators are devices that restore the normal heartbeat by sending an electric pulse or shock to the heart. They are used to prevent or correct an arrhythmia, a heartbeat that is uneven or slow or fast. The type of expenditure is public, or private. The products used are instruments/equipment, and disposables. The various end-users are hospitals and clinics, diagnostic laboratories, and others. The cardiovascular devices market research report is one of a series of new reports from The Business Research Company that provides cardiovascular devices market statistics, including cardiovascular devices industry global market size, regional shares, competitors with a cardiovascular devices market share, detailed cardiovascular devices market segments, market trends and opportunities, and any further data you may need to thrive in the cardiovascular devices industry. This cardiovascular devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cardiovascular devices market grew from $59.55 billion in 2022 to $64.39 billion in 2023 at a compound annual growth rate (CAGR) of 8.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cardiovascular devices market is expected to grow to $83.35 billion in 2027 at a CAGR of 6.7%. Leadless pacemakers are being used for certain medical conditions such as slow heart rate (bradycardia), as they provide a less-invasive alternative to conventional pacemakers. A leadless pacemaker is a self-contained device that is inserted in the right ventricle of the heart without incisional access, leads, or a surgical pocket. Furthermore, the medical procedure for a leadless pacemaker can be performed in under 30 minutes, with few postprocedural restrictions. These devices are gaining popularity as they eliminate complications related to lead placement which includes cardiac perforation, pneumothorax, and lead dislodgement. Major companies manufacturing leadless pacemakers are Medtronic and Abbott. Major companies in the cardiovascular devices market include Medtronic Inc., Boston Scientific Corporation, Abbott Laboratories, Edwards Lifesciences, Cardinal Health, Inc., Johnson & Johnson, Terumo Corporation, Getinge Group, Teleflex Inc., and Becton Dickinson. North America was the largest region in the global cardiovascular devices market in 2022. Western Europe was the second largest region in the global cardiovascular devices market. Africa. was the smallest region in the global cardiovascular devices market. The regions covered in the cardiovascular devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the cardiovascular devices market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The cardiovascular devices market consists of sales of biventricular devices, and implantable cardiac loop recorders that are used for monitoring and treatment of cardiovascular disorders. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cardiovascular devices market is segmented - 1) By Type: Cardiovascular Surgery Devices And Equipment, Cardiac Rhythm Management (CRM) Devices And Equipment, Interventional Cardiology Devices And Equipment, Defibrillator Devices And Equipment, Peripheral Vascular Devices And Equipment, Prosthetic Heart Valve Devices And Equipment, Electrophysiology Devices And Equipment, Cardiac Assist Devices And Equipment 2) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables

Coronary atherectomy devices are used to remove atherosclerosis from coronary blood vessels. Atherectomy devices were developed to permit drilling, grinding, or sanding of atheroma, calcium, and excess cellular material from the site of coronary occlusion or stenosis. The main products of coronary atherectomy devices are directional atherectomy devices, orbital atherectomy devices, photo-ablative atherectomy devices, rotational atherectomy devices, and others. The rotational atherectomy device is a long catheter with an oval-shaped burr that is encrusted with microscopic diamond embedded surface tip. The various application involved are peripheral vascular, cardiovascular, and neurovascular that are used by end-users such as hospitals and surgical centers, ambulatory care centers, research laboratories, and academic institutes. The coronary atherectomy devices market research report is one of a series of new reports from The Business Research Company that provides coronary atherectomy devices market statistics, including coronary atherectomy devices industry global market size, regional shares, competitors with a coronary atherectomy devices market share, detailed coronary atherectomy devices market segments, market trends and opportunities, and any further data you may need to thrive in the coronary atherectomy devices industry. This coronary atherectomy devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global coronary atherectomy devices market grew from $0.18 billion in 2022 to $0.2 billion in 2023 at a compound annual growth rate (CAGR) of 10.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The coronary atherectomy devices market is expected to grow from $0.28 billion in 2027 at a CAGR of 8.5%. The increasing prevalence of cardiovascular diseases (CVDs) has resulted in an increased demand for atherectomy devices for the treatment of CVDs. The increased prevalence of cardiovascular diseases can be attributed to the use of smoking, physical inactivity, and an unhealthy diet. For instance, according to the Centers for Disease Control and Prevention, in 2020, heart diseases causes 697,000 deaths. It is a group of disorders of the heart and blood vessels and includes cerebrovascular disease, rheumatic heart disease, coronary heart disease, and other conditions. According to the British Heart Foundation, 2020, Coronary Heart Disease is responsible for around 64,000 deaths in the UK each year, an average of 180 people each day, or one death around every eight minutes. One in seven men and one in twelve women in the United Kingdom die from coronary heart disease. Therefore, increasing the prevalence of cardiovascular diseases is expected to drive the growth of the global coronary atherectomy devices market. During the forecast period, the long approval processes for medical devices are expected to restrain the growth of the coronary atherectomy devices market. Regulatory bodies have imposed strict labeling requirements, pre-market approval, medical device reporting, and the launching of products. These devices fall under the Class II category and are considered to be highly risky. Therefore, stringent government regulations may hamper the growth of the coronary atherectomy devices market. Large coronary atherectomy equipment market manufacturers are strategically partnering and collaborating with start-ups and mid-sized companies to broaden products and services. For instance, in 2021, Cardiovascular Systems, Inc. has announced the acquisition of peripheral support catheters from Wavepoint Medical LLC with an undisclosed amount. This acquisition helps Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company operate on developing and commercializing creative solutions for treating vascular and coronary disease. In July 2020, BD (Becton, Dickinson and Company), a US-based medical devices company, acquired Straub Medical AG for an undisclosed amount. The acquisition would allow BD to extend its offerings in the fields of thrombectomy and atherectomy and strenhthen its portfolio in stents, stent grafts, angioplasty and scoring balloons. Straub Medical AG is a Switzerland-based developer of medical atherectomy and thrombectomy devices. Major players in the coronary atherectomy devices market are Boston Scientific, Philips, Cardiovascular Systems, Spectranetics, Medtronic, Avinger, BIOTRONIK, Arterial Remodeling Technologies, Atrium Medical, and B. Braun Melsungen. North America was the largest region in the coronary atherectomy devices market in 2022. Western Europe was the second largest region in the global coronary atherectomy devices market report. Africa. was the smallest region in the global coronary atherectomy devices market. The regions covered in the global coronary atherectomy devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the coronary atherectomy devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The coronary atherectomy devices market consists of sales of directional atherectomy devices, orbital atherectomy devices, photo-ablative atherectomy devices, rotational atherectomy devices, and others that are used to treat coronary atherectomy. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global coronary atherectomy devices market is segmented - 1) By Product: Directional Atherectomy Devices, Orbital Atherectomy Devices, Photo-Ablative Atherectomy Devices, Rotational Atherectomy Devices, Other Products 2) By Application: Peripheral Vascular, Cardiovascular, Neurovascular 3) By End User: Hospitals & Surgical Centers, Ambulatory Care Centers, Research Laboratories & Academic Institutes

Medical equipment are devices that can be instrument, apparatus or machine that can be used in the prevention, diagnosis or treatment of illness or disease, or for detecting, measuring, restoring, correcting or modifying the structure or function of the body for health purpose. The main types of medical equipment are in-vitro diagnostics, dental equipment and supplies, ophthalmic devices, diagnostic imaging equipment, cardiovascular devices, hospital supplies, surgical equipment, orthopedic devices, patient monitoring devices, diabetes care devices, nephrology and urology devices, ENT devices, anesthesia and respiratory devices, neurology devices, and wound care devices. In-vitro diagnostics are tests done on samples like blood or tissue that is taken from the human body. In-vitro diagnostics will detect diseases or other conditions and are used to monitor a person’s overall health to cure, treat, or prevent diseases. The type of expenditure involved is public and private. The various product are instruments/equipment and disposables. The various end users involved are hospitals and clinics, homecare, diagnostics centres, and others. The medical equipment market research report is one of a series of new reports from The Business Research Company that provides medical equipment market statistics, including medical equipment industry global market size, regional shares, competitors with a medical equipment market share, detailed medical equipment market segments, market trends and opportunities, and any further data you may need to thrive in the medical equipment industry. This medical equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global medical equipment market grew from $639.75 billion in 2022 to $695.05 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The medical equipment market is expected to grow to $922.39 billion in 2027 at a CAGR of 7.3%. The rise in sedentary jobs, busy lifestyles, and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes, and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. This is increasing the demand for medical devices used in the diagnosis, prognosis, and treatment of several diseases, thereby driving the demand for medical equipment. These factors are expected to increase the patient pool globally, thereby driving the market during the forecast period. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to customer data protection such as the European Union's General Data Protection Regulation (GDPR), changes to equipment approval procedures, and other regulatory changes. For instance, according to cookieyed data 2021, in the US, PwC reported that 68% of 200 businesses surveyed intended to spend between $1 million and $10 million to comply with GDPR regulations. The GDPR regulation is an EU law on data protection and privacy of individuals residing in the European Union and the European Economic Area (EEA). It also regulates the export of personal data outside the EU and EEA areas. Additionally, the FDA is requesting more clinical data to support claims, therefore increasing the time to process 510(k)s by over 55% over the last decade. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts a strain on investments relating to new product development, thereby affecting the growth of the medical equipment market. Device performance and patient data are available to healthcare service providers and are helping them to improve patient monitoring and overall care quality. Some companies are integrating medical device data with EMR (Electronic Medical Records) to improve transparency and collaboration. As consumer wearables are becoming more common, patient data volumes are increasing and companies are investing in deploying data management, warehousing, and security technologies. For example, Medtronic launched a tool to augment their cardiac devices to securely transfer device data to doctors and allow them to monitor the critical health indicators of their patients. Major companies in the medical equipment market include Medtronic Inc., Abbott Laboratories, Johnson & Johnson, Cardinal Health, Inc., Becton Dickinson, Siemens AG, STRYKER CORPORATION, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., and Boston Scientific Corporation. North America was the largest region in the global medical equipment market in 2022. Asia-Pacific was the second largest region in the global medical equipment market. The regions covered in the medical equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the medical equipment market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The medical equipment market consists of sales of devices used in the diagnosis, treatment and monitoring of medical conditions. The market includes diagnostic devices, imaging devices, surgical devices and patient monitoring devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global medical equipment market is segmented - 1) By Type: In-Vitro Diagnostics, Dental Equipment And Supplies, Ophthalmic Devices, Diagnostic Imaging Equipment, Cardiovascular Devices, Hospital Supplies, Surgical Equipment, Orthopedic Devices, Patient Monitoring Devices, Diabetes Care Devices, Nephrology And Urology Devices, ENT Devices, Anesthesia And Respiratory Devices, Neurology Devices, Wound Care Devices 2) By Type of Expenditure: Public, Private 3) By Product: Instruments/Equipment, Disposables 4) By End User: Hospitals And Clinics, Homecare, Diagnostics Centers, Other End Users Subsegments Covered: Point-of-Care Diagnostics Devices And Equipment, Immunochemistry Diagnostic Devices And Equipment, Clinical Chemistry Diagnostics Devices And Equipment, Molecular Diagnostics Devices And Equipment, Microbiology Diagnostic Devices And Equipment, Hemostasis Diagnostic Devices And Equipment, Hematology Diagnostic Devices And Equipment, Immunohematology Diagnostic Devices And Equipment, Therapeutic Dental Equipment, General Dental Devices And Equipment, Dental Diagnostic Imaging Devices And Equipment, Dental Surgical Devices And Equipment, Vision Care Devices And Equipment, Cataract Surgery Devices And Equipment, Refractive Surgery Devices And Equipment, Diagnostic And Monitoring Ophthalmic Devices And Equipment, X-Ray Systems Devices And Equipment, Ultrasound Systems Devices And Equipment, Computed Tomography (CT) Scanners Devices And Equipment, Magnetic Resonance Imaging Systems Devices And Equipment, Cardiovascular Monitoring And Diagnostic Devices And Equipment, Nuclear Imaging Devices And Equipment, Cardiovascular Surgery Devices And Equipment, Cardiac Rhythm Management (CRM) Devices And Equipment, Interventional Cardiology Devices And Equipment, Defibrillator Devices And Equipment, Peripheral Vascular Devices And Equipment, Prosthetic Heart Valve Devices And Equipment, Electrophysiology Devices And Equipment, Cardiac Assist Devices And Equipment, Disposable Hospital Supplies, Sterilization Equipment And Disinfectants, Mobility Aids And Transportation Equipment, Operating Room Equipment, Surgical Sutures And Staples, Handheld Surgical Devices And Equipment, Electrosurgical Devices And Equipment, Joint Reconstruction Devices And Equipment, Spinal Surgery Devices And Equipment, Trauma Fixation Devices And Equipment, Orthobiologics Devices And Equipment, Arthroscopy Devices And Equipment, Orthopedic Braces And Support Devices And Equipment, Craniomaxillofacial (CMF) Devices And Equipment, Orthopedic Prosthetics, Orthopedic Accessories,, Fetal And Neonatal Monitoring Devices, Weight Monitoring And Body Temperature Monitoring Devices And Equipment, Vital Parameter Monitoring Devices And Equipment, Remote Patient Monitoring Devices And Equipment, Blood Glucose Test Strips, Insulin Pens, Syringes, Pumps And Injectors, Lancing Devices And Equipment, Continuous Glucose Monitoring Devices And Equipment, Blood Glucose Meters, Dialysis Devices And Equipment, Urinary Stone Treatment Devices And Equipment, Urinary Incontinence & Pelvic Organ Prolapse Devices And Equipment, Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment, Endoscopy Devices And Equipment, Hearing Aid Devices And Equipment, Hearing Diagnostic Devices And Equipment, ENT Surgical Devices And Equipment, Hearing Implants, Voice Prosthesis Devices And Equipment, Nasal Splints, Respiratory Devices And Equipment (Therapeutic And Diagnostic), Anesthesia Machines, Anesthesia Disposables, Respiratory Disposables, Cerebrospinal Fluid Management (CSF) Devices And Equipment, Interventional Neurology Devices And Equipment, Neurosurgery Devices And Equipment, Neurostimulation Devices, Traditional Adhesive Dressings, Negative-pressure Wound Therapy (NPWT), Traditional Gauze Dressings, Advanced Wound Care Devices